An old, controversial Pfizer drug shows mid-stage efficacy against narcolepsy
Reboxetine never got much traction in the US. Marketed as an anti-depressant in Europe for the past 20 years, the Pfizer drug was provisionally FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
